Xi声Pharma Partners with Schrodinger on Drug Discovery Collaboration on July 10

According to Xiansheng Pharmaceutical (02096), the company announced on July 10, 2026 a global drug discovery and development collaboration agreement with U.S.-based Schrodinger, a leader in physics-driven computational drug design. Schrodinger will lead the joint discovery phase using its artificial intelligence and physics-based platform for computer-aided drug design and optimization. Following discovery, Xiansheng will oversee preclinical research and clinical development. Under the agreement, Schrodinger is eligible for milestone payments and tiered royalties on net product sales.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments